AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A method of ~~modulating~~ inhibiting inflammation within an immune privileged site in an animal ~~by~~ comprising delivering an effective amount of a soluble Fas ligand fragment ~~comprising the extracellular domain of a full length Fas ligand, or a derivative thereof~~, behind the blood-tissue barrier of the immune privileged site, wherein said soluble Fas ligand fragment~~, or derivative thereof,~~ has the ability to induce apoptosis in Fas expressing cells.

2. Canceled.

3. (Currently Amended) The method according to claim 1, wherein said effective amount of the soluble Fas ligand fragment~~, or derivative thereof,~~ is administered to said animal by a method selected from the group comprising: intrathecal administration; intraventricular administration; and intracisternal administration.

4. (Currently Amended) The method according to claim 1, wherein said soluble Fas ligand fragment is a recombinant polypeptide.

5. (Currently Amended) The method according to claim 1, wherein said soluble Fas ligand fragment ~~comprises at least~~ consists essentially of amino acids 103-281 of a human full length Fas ligand.

6. (Previously presented) The method according to claim 1 [2], wherein said immune privileged site is the CNS.

7. (Previously presented) The method according to claim 6, wherein said inflammation is associated with an inflammatory disease.

8. (Previously presented) The method according to claim 7, wherein said inflammatory disease is multiple sclerosis.

9-14. Canceled.

15. (Previously Presented) The method according to claim 1, wherein said animal is a mammal.

16. (Previously Presented) The method according to claim 15, wherein said animal is a human.

17-19. Canceled.

20. (Currently Amended) A method of modulating inflammation in an immune privileged site in an animal through the *in vivo* induction of apoptosis in Fas expressing cells, comprising delivering an effective amount of a soluble Fas ligand fragment ~~comprising the extracellular domain of a full length Fas ligand, or a derivative thereof,~~ behind the blood-tissue barrier of the immune privileged site.

21. (Previously Presented) The method according to claim 20, wherein said animal is a mammal.

22. (Previously Presented) The method according to claim 21, wherein said mammal is a human.

23-47. Canceled.

48. (Withdrawn) The method according to claim 1, wherein said Fas ligand fragment, or derivative thereof, is delivered to said animal by means of expressing a nucleic acid encoding said Fas ligand fragment, or derivative thereof.

49. (Withdrawn) The method according to claim 48, wherein said nucleic acid is administered to said animal in a form selected from the group comprising: cDNA, plasmid DNA, a liposome, a viral vector, or a transformed cell.

50. (Currently Amended) The method according to claim 20, wherein said effective amount of the soluble Fas ligand fragment~~, or derivative thereof,~~ is administered to said animal by a method selected from the group comprising: intrathecal administration; intraventricular administration; and intracisternal administration.

51. (Withdrawn) The method according to claim 20, wherein said Fas ligand fragment, or derivative thereof, is delivered to said animal by means of expressing a nucleic acid encoding said Fas ligand fragment, or derivative thereof.

52. (Withdrawn) The method according to claim 51, wherein said nucleic acid is administered to said animal in a form selected from the group comprising: cDNA, plasmid DNA, a liposome, a viral vector, or a transformed cell.

53. (Currently Amended) The method according to claim 20, wherein said soluble Fas ligand fragment is a recombinant polypeptide.

54. (Currently Amended) The method according to claim 20, wherein said soluble Fas ligand fragment ~~comprises at least~~ consists essentially of amino acids 103-281 of a human full length Fas ligand.

55. (Previously Presented) The method according to claim 20, wherein said immune privileged site is the CNS.

56. (Previously Presented) The method according to claim 55, wherein said inflammation is associated with an inflammatory disease.

57. (Previously Presented) The method according to claim 56, wherein said inflammatory disease is multiple sclerosis.

58. (New) The method of claim 1, wherein said soluble Fas ligand fragment comprises the extracellular domain of a full length Fas ligand.

59. (New) The method of claim 1, wherein said Fas expressing cells are inflammatory cells.

60. (New) The method of claim 59, wherein said inflammatory cells are selected from the group consisting of encephalitogenic T cells, activated T cells, and macrophages.

61. (New) The method of claim 1, wherein said delivering is done prior to the onset of inflammation within said immune privileged site.